Skip to Main Content

A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors

Conditions

Phase I | Unknown Sites

Phase I

What is the purpose of this trial?

To study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in patients with Advanced Solid Tumors

  • Trial with
    Stemline Therapeutics, Inc.
  • Start Date
    08/18/2016
  • End Date
    11/30/2019
Trial Image

For more information about this study, contact:

Ingrid Palma

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/29/2020
  • Study HIC
    #1511016798